• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antidepressants Harm Some With Bipolar Depression

Antidepressants Harm Some With Bipolar Depression

March 26, 2021
Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD. Dr. Aiken has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Ghaemi SN et al, J Clin Psychiatry 2021;82(1):19m13136

Study TYPE: Randomized, double-blind, placebo-controlled trial

Antidepressants are controversial in bipolar depression, in part because we don’t have enough well-designed studies to clarify their role. The most rigorous trials have come up negative, and many of the positive ones suffer from design flaws (eg, lack of placebo, small sample size, or enriched design). On the other hand, few of these studies have uncovered significant rates of manic switching, as long as a mood stabilizer is on board. This new study is the first placebo-controlled trial to examine the long-term effects of an SSRI in bipolar disorder.

The study, which is summarized in the table below, randomized 119 patients with bipolar I or II depression to citalopram or placebo as an add-on to a “traditional” mood stabilizer (“traditional” means an antipsychotic was not allowed as the sole mood stabilizer, but lithium, valproate, carbamazepine, and lamotrigine were). Citalopram was started at 10 mg/day and increased by 10 mg every week as needed toward a max of 60 mg/day (mean of 27 mg/day).
Table: Citalopram in Bipolar Depression

Table: Citalopram in Bipolar Depression

(Click to view full-size PDF.)

Compared to placebo, citalopram brought no significant differences in response, remission, or change in depressive symptoms after acute (6-week) and long-term (12-month) follow-up. Likewise, there was no difference in manic symptoms or new episodes of hypomania or mania at either time point, and analysis of the month-by-month trend in symptoms also revealed no differences.

The authors then broke the data down by three bipolar subtypes: type I, type II, and rapid cycling. No differences emerged between types I and II, but those who entered the study with a recent history of rapid cycling (n = 33) had significant worsening of manic symptoms (a mean 2-point increase over placebo on the MRS-SAD mania scale).

The main finding—that an antidepressant did not help and may have harmed the rapid cycling group—is supported by earlier studies. The main weakness was the dropout rate, which although high (30% short-term, 69% long-term) was within the range seen in maintenance bipolar trials. Dropouts were handled conservatively with intent-to-treat analysis and were evenly distributed between the two groups. Most were patients who exited the trial because they required further therapeutic intervention for worsening symptoms.

TCPR’s Take
Whether you fall in the pro, con, or uncertain camp on antidepressants in bipolar disorder, this study suggests they are not very helpful and—in line with earlier work—should be avoided in rapid cycling cases. Rapid cycling is difficult to detect and includes patients with no recent manias but at least 4 discrete episodes of depression in the past year. Monitor carefully for rapid cycling with a mood chart in patients with bipolar disorder who take an antidepressant.


podcasts

To learn more, listen to our 4/19/21 podcast, “Antidepressants in Bipolar: What the Experts Actually Do in Practice.” Search for “Carlat” on your podcast store.

General Psychiatry
KEYWORDS antidepressants bipolar-depression bipolar_disorder
    Aiken
    Chris Aiken, MD.

    Omega-3s and Metabolic Risks in Schizophrenia

    More from this author
    www.thecarlatreport.com
    Issue Date: March 26, 2021
    SUBSCRIBE NOW
    Table Of Contents
    In Brief: What Causes Affective Psychosis?
    Six Tips for Working With Older Adults
    Mood, Cognition, and Metabolic Health
    Antidepressants Harm Some With Bipolar Depression
    Uncertain Results for Eszopiclone in PTSD
    CME Post-Test - Metabolism and Mental Health, TCPR, April 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.